RESUMO
This article evaluated the effect of the Shanghai protocol on a hypergonadotropic hypogonadism patient undergoing in vitro fertilization (IVF) treatment. Hypergonadotropic hypogonadism was characterized by low sex hormone levels and elevated gonadotropins, leading to infertility. Poor ovarian response and failed pregnancy outcomes were the results of previous IVF treatments using conventional stimulation methods. The 37-year-old female patient was advised to follow the Shanghai protocol, which involved gonadotropin stimulation following pituitary suppression with a long-acting gonadotropin-releasing hormone agonist (GnRH-a). The Shanghai protocol significantly improved the ovarian response. Two oocytes were retrieved, and one 4AA grade (number 4 represents an expanded blastocyst, the embryo is large, and the zona is thin; first A represents the inner cell mass of numerous and tightly packed cells; second A represents trophectoderm, with many cells organized in epithelium) embryo was formed. According to her previous result, the patient with hypergonadotropic hypogonadism who had one unsuccessful IVF cycle after visiting our infertility center was advised of the Shanghai protocol. Establishing these results and enhancing the Shanghai protocol's implementation to this specific patient treatment, clinical pregnancy was achieved.
RESUMO
This case report focuses on a couple facing primary infertility, where the male partner exhibited asthenoteratozoospermia and high DNA fragmentation. The treatment approach involved three cycles of intracytoplasmic sperm injection (ICSI), an assisted reproductive technology (ART), to indicate and address the specific challenges posed by male factor infertility. The initial two attempts failed as DNA fragmentation was high, which was observed on days 4 and 3 of abstinence, respectively. In the third cycle, DNA fragmentation was low on day 2 of the abstinence period, resulting in the successful formation and cryopreservation of embryos. Subsequently, three months later, frozen embryo transfer (ET) was done. This was followed by a positive ß-human chorionic gonadotropin (hCG) test after 14 days that confirmed biochemical pregnancy, and successful conception was determined by ultrasound detection of the visible sac with fetal pole. This report underscores the critical importance of treatment plans for individual patients, especially considering the impact of abstinence periods on sperm DNA fragmentation. The findings promote a personalized approach to assisted reproductive techniques, enhancing the success rate. It is recommended that further comprehensive studies be conducted to validate and anticipate these observations.
RESUMO
The case study examined a 32-year-old female and her 35-year-old partner who had experienced infertility attributed to the wife's irregular ovulation. Despite the male partner demonstrating normal reproductive parameters, he had a medical history involving hypertension. The woman also had a history of hypertension and chikungunya, which was accompanied by fever and joint pain in 2019. Due to the woman's allergic reaction to traditional ovulation stimulatory medications, the approach to assisted reproductive technologies (ART) had shifted towards employing the short agonist stop (SAS) regimen. Controlled ovarian stimulation had been achieved by administering recombinant follicular hormone, gonadotropin-releasing hormone (GnRH), and estrogen. The SAS protocol had been introduced to counter premature ovulation and synchronize follicular development. Following two successful ovum pickup procedures resulting in the retrieval of six embryos, the initial frozen embryo transfer took place in April 2022. Daily progesterone supplementation had been administered to sustain the patient's luteal phase. A subsequent human chorionic gonadotropin (ß-hCG) test performed on the 14th day post-embryo transfer confirmed a positive pregnancy diagnosis, with a measured outcome of 2026 mIU/mL. This case highlighted the potential impact of medication allergies on fertility outcomes and underscored the unique approach of the SAS protocol in managing allergic responses during in vitro fertilization (IVF) procedures. Despite the patient's history of allergic reactions to conventional ovulation stimulatory medications, the study concluded that the implementation of the brief agonist stop strategy had resulted in a successful clinical pregnancy.
